Octreotide Acetate

Antigrowth Hormone · Somatostatin analogue

Indications

Sandostatin Inj 0.05 mg/0.1 mg: Relief of symptoms associated with gastro-entero-pancreatic endocrine (GEP) tumours, carcinoid tumours. VIPomas and glucagonomas. Prevention of complications following pancreatic surgery. Short-term treatment of acromegaly prior to pituitary surgery. Long-term treatment in whom surgery, dopamine agonists or radiotherapy are ineffective or inappropriate, or interim period until radiotherapy effective. Sandostatin LAR Inj: Relief of symptoms associated with gastro-entero-pancreatic endocrine (GEP) tumours including carcinoid tumours. VIPomas and glucagonomas in patients controlled by subcutaneous Sandostatin. Acromegaly in patients controlled by subcutaneous Sandostatin in whom surgery, dopamine agonists or radiotherapy are ineffective or inappropriate, or interim period until radiotherapy becomes effective.

Dosage

Sandostatin Inj 0.05 mg/0.1 mg: GEP tumours: Adults: Initially 0.05 mg once or twice daily by SC Inj increasing to 0.2 mg three times daily if necessary. Carcinoid crises: Adults: 0.05 mg by IV Inj diluted with saline and given as a bolus; see literature. Pancreatic surgery: Adults: 0.1 mg thrice daily by SC Inj for 7 days, starting 1 hr before laparotomy. Children: Not recommended. Acromegaly: Adults: 0.1-0.2 mg three times daily by SC Inj. Children: Not recommended. Sandostatin LAR Inj: GEP tumours, Carcinoid crises: Adults: After control has been established with subcutaneous Sandostatin, administer 20 mg of Sandostatin LAR by deep intragluteal inj every 4 wk for 3 mth. Continue with same dose of subcutaneous Sandostatin for 2 wk after starting Sandostatin LAR. Reassess after 3 mth, adjust subsequent doses according to response. See literature. Acromegaly: When control established…

Administration

IM: Depot formulation: Administer immediately after reconstitution, administered in gluteal muscle. Avoid deltoid administration. IV: Regular injection only. IV administration may be IVP, IVPB or continuous infusion. IVP should be administered undiluted over 3 min. IVPB should be administered over 15-30 min. Continuous IV infusion rates have ranged from 25-50 mcg/hour for the treatment of esophageal variceal bleeding. Compatibility: Stable in D5W, NS. Incompatible with fat emulsion 10%. Stability: Should be stored under refrigeration. Ampoules may be stored at room temperature for up to 14 days when protected from light. Stability of parenteral admixture in NS at room temperature (25°C) and at refrigeration temperature (4°C) is 48 hours.

Adverse Effects

Inj site reaction. GI disturbances. Gallstones, biliary colic. Rarely, persistent hyperglycaemia, hypoglycaemia, hair loss, hepatic dysfunction, acute pancreatitis.

Risk Factor (Pregnancy/Lactation)

Contraindications: Pregnancy, lactation. Precautions: Sudden escape from symptomatic control may occur. Diabetics may show reduced hypoglycaemic requirements. In case of carcinoid tumour, stop if no beneficial effect seen within one week. In long term therapy, monitor thyroid function and for gall stones.

Interactions

Cyclosporin, cimetidine, bromocriptine.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.